What is the 13F Pro Quality Score for AMGN?

13F Pro ranks AMGEN INC (AMGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AMGN's current score at https://13fpro.ai/research/AMGN (free sign-up required for the full ranking).

Which hedge funds own the most AMGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AMGN include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AMGN as soon as new 13F filings post.

Where does 13F Pro source AMGN data?

All AMGEN INC fundamentals and ownership data come directly from SEC EDGAR. AMGEN INC files with the SEC under CIK 318154. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AMGN in?

AMGEN INC (AMGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AMGN research updated on 13F Pro?

AMGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AMGEN INC(AMGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 318154 AMGN stock profile & AI dashboard →

13F Pro Quality Score

79.5/100

Rank #53 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

72.7/100

Profitability

89.1/100

Balance Sheet

84.8/100

Earnings Quality

66.7/100

Free Cash Flow

81.8/100

Institutional Flow

38.1/100

Revenue Scale

96.0/100

Dilution Risk

49.4/100

AMGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AMGEN INC (AMGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMGN at 79.5/100 on a 32-signal composite quality model, placing it at rank #53 of 2,879 stocks — the top 5% of the AI-ranked universe. AMGN scores in the top quartile across revenue scale (96.0), profitability (89.1), balance sheet strength (84.8). Areas of concern include institutional flow (38.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 49.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AMGEN INC reports quarterly revenue of $8.6B, net income of $1.8B, an operating margin of 30.9%. Top institutional holders of AMGN by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. AMGN trades on the Nasdaq exchange and files with the SEC under CIK 318154. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AMGEN INC directly from SEC EDGAR. AMGEN INC's 13F Pro composite quality score has ranged between 64 and 86 since 2021, currently 79.5 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about AMGEN INC

Quirks, history, and lore behind AMGN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mega-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue around $33 billion, with a fat profit margin north of 25% — this is not a company that sells aspirin at Walgreens.
3
The History
Founded in 1980 as one of the first-ever biotechnology companies, it pioneered turning living cells into blockbuster medicines instead of old-school chemistry.
4
The Secret
Its early success was built on drugs that help the body make red blood cells and fight infections after chemotherapy — not glamorous, but worth billions.
5
The Lore
Its hit drug Enbrel — for rheumatoid arthritis — was once among the best-selling drugs on Earth, and the company has long been the quiet giant that other biotech firms dream of becoming.
6
The Giveaway
The granddaddy of Thousand Oaks biotech, its name is a mashup of "applied molecular genetics" — and yes, that's basically their whole elevator pitch since 1980.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.6B

Net Income

Q1 2026

$1.8B

Free Cash Flow

Q1 2026

$1.5B

Operating Margin

Q1 2026

30.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.0% YoY

$36.75BFY 2025

FY22 $26.32BFY23 $28.19BFY24 $33.42BFY25 $36.75B

Net Income

+88.5% YoY

$7.71BFY 2025

FY22 $6.55BFY23 $6.72BFY24 $4.09BFY25 $7.71B

Operating Income

+25.1% YoY

$9.08BFY 2025

FY22 $9.57BFY23 $7.90BFY24 $7.26BFY25 $9.08B

EPS (Diluted)

+88.2% YoY

$14.23FY 2025

FY22 $12.11FY23 $12.49FY24 $7.56FY25 $14.23

Total Assets

-1.4% YoY

$90.59BFY 2025

FY22 $65.12BFY23 $97.15BFY24 $91.84BFY25 $90.59B

Total Debt

-7.0% YoY

$59.20BFY 2025

FY22 $40.54BFY23 $66.06BFY24 $63.65BFY25 $59.20B

Op. Cash Flow

-13.3% YoY

$9.96BFY 2025

FY22 $9.72BFY23 $8.47BFY24 $11.49BFY25 $9.96B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$36.75B +10.0%	$33.42B +18.6%	$28.19B +7.1%	$26.32B +1.3%	$25.98B +2.2%	$25.42B
Net Income	$7.71B +88.5%	$4.09B -39.1%	$6.72B +2.5%	$6.55B +11.2%	$5.89B -18.9%	$7.26B
Operating Income	$9.08B +25.1%	$7.26B -8.1%	$7.90B -17.4%	$9.57B +25.2%	$7.64B -16.4%	$9.14B
EPS (Diluted)	$14.23 +88.2%	$7.56 -39.5%	$12.49 +3.1%	$12.11 +17.8%	$10.28 -16.5%	$12.31
Total Assets	$90.59B -1.4%	$91.84B -5.5%	$97.15B +49.2%	$65.12B +6.5%	$61.16B -2.8%	$62.95B
Total Debt	$59.20B -7.0%	$63.65B -3.6%	$66.06B +63.0%	$40.54B +21.4%	$33.40B +1.0%	$33.08B
Operating Cash Flow	$9.96B -13.3%	$11.49B +35.6%	$8.47B -12.9%	$9.72B +5.0%	$9.26B -11.8%	$10.50B

Get alerted when AMGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AMGEN INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AMGN

BlackRock, Inc.
$16.6B47,100,472 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.3B35,014,232 sh
STATE STREET CORP
$10.7B30,548,488 sh
Capital World Investors
$10.3B29,288,343 sh
MORGAN STANLEY
$5.6B15,836,058 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.4B15,430,524 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$5.1B14,621,148 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$4.5B12,773,386 sh
PRIMECAP MANAGEMENT CO/CA/
$3.1B8,874,129 sh
Capital International Investors
$2.5B7,122,275 sh

Fund	Value	Shares
BlackRock, Inc.	$16.6B	47,100,472
VANGUARD CAPITAL MANAGEMENT LLC	$12.3B	35,014,232
STATE STREET CORP	$10.7B	30,548,488
Capital World Investors	$10.3B	29,288,343
MORGAN STANLEY	$5.6B	15,836,058
GEODE CAPITAL MANAGEMENT, LLC	$5.4B	15,430,524
VANGUARD PORTFOLIO MANAGEMENT LLC	$5.1B	14,621,148
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$4.5B	12,773,386
PRIMECAP MANAGEMENT CO/CA/	$3.1B	8,874,129
Capital International Investors	$2.5B	7,122,275

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AMGN on your watchlist

Track score changes the day AMGEN INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AMGN a good stock to buy?

13F Pro's AI-powered analysis of AMGEN INC (AMGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMGN are available on the AMGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AMGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AMGEN INC's investment landscape.